Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients

NCT02939287 is registered in ClinicalTrials.gov with Rush University Medical Center as lead sponsor.

NCT NCT02939287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02939287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients
Lead sponsor
Rush University Medical Center
Phase
Phase 3
Overall status
Completed
Start date
September 23, 2017
Completion date
December 1, 2022
Enrollment
52 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nausea, vomiting